Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia
NCT03790085Phase 1Unknown
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Sep 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in schizophrenia comparing Risperidone, Olanzapine and Aripiprazole (3 arms). Primary endpoints: Positive and Negative Syndrome Scale at 8 weeks and Clinical Global Impression at 8 weeks. Status: unknown.
02
Drugs
risperidoneolanzapinearipiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03790085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03790085.